Zentalis Pharmaceuticals (ZNTL) Other financing activities (2019 - 2026)
Zentalis Pharmaceuticals (ZNTL) posted quarterly Other financing activities of $331000.0 for Q1 2026, up 75.13% year-over-year from $189000.0 in Q1 2025, and up 187.83% quarter-over-quarter from $115000.0 in Q3 2025.
Powered by 
Analysis
Zentalis Pharmaceuticals (ZNTL) Other financing activities (2019 - 2026) Analysis & Trends
Zentalis Pharmaceuticals' Other financing activities history runs 7 years deep, the most recent figure standing at $331000.0 for Q1 2026.
- In Q1 2026, Other financing activities rose 75.13% year-over-year to $331000.0; the TTM figure through Mar 2026 stood at $446000.0 (up 53.79% YoY), while the FY2025 annual figure was $304000.0, down 12.89% from the prior year.
- Other financing activities for Q1 2026 stood at $331000.0, up from $115000.0 in the prior quarter.
- The five-year high for Other financing activities was $1.3 million in Q1 2022, with the low at $9000.0 in Q2 2024.
- The 5-year median for Other financing activities is $309000.0 (2023), against an average of $440615.4.
- The sharpest annual moves came in 2023 and 2024: Other financing activities surged 495.57% in 2023, then plunged 99.04% in 2024.
- Zentalis Pharmaceuticals' Other financing activities stood at $1.1 million in 2022, then sank by 72.31% to $309000.0 in 2023, then tumbled by 70.23% to $92000.0 in 2024, then climbed by 25.0% to $115000.0 in 2025, then jumped by 187.83% to $331000.0 in 2026.
- Business Quant data shows ZNTL's Other financing activities at $331000.0 in Q1 2026, $115000.0 in Q3 2025, and $189000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Zentalis Pharmaceuticals | 282.81 Mn | 282.81 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 65,000.00 |
| Mar 31, 2026 | 331,000.00 |
| Sep 30, 2025 | 115,000.00 |
| Mar 31, 2025 | 189,000.00 |
| Sep 30, 2024 | 92,000.00 |
| Jun 30, 2024 | 9,000.00 |
| Mar 31, 2024 | 248,000.00 |
| Sep 30, 2023 | 309,000.00 |
| Jun 30, 2023 | 941,000.00 |
| Mar 31, 2023 | 373,000.00 |
| Dec 31, 2022 | 1.12 Mn |
| Sep 30, 2022 | 589,000.00 |
| Jun 30, 2022 | 158,000.00 |
| Mar 31, 2022 | 1.26 Mn |
| Dec 31, 2021 | 3.66 Mn |
| Sep 30, 2021 | 3.65 Mn |
| Jun 30, 2021 | 386,000.00 |
| Jun 30, 2020 | 171.73 Mn |
| Mar 31, 2020 | 754,000.00 |
| Dec 31, 2019 | 46,000.00 |